Takeda Pharmaceutical annual stock-based compensation
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Takeda Pharmaceutical Stock-Based Compensation Growth & History (TAK)
Takeda Pharmaceutical's stock-based compensation was ¥72.78B for fiscal 2026.
View full Takeda Pharmaceutical company overviewTakeda Pharmaceutical annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | ¥72.78B | −¥810.0M | −1.10% |
| 2025 | 2025-03-31 | ¥73.58B | ¥2.08B | +2.90% |
| 2024 | 2024-03-31 | ¥71.51B | ¥10.49B | +17.18% |
| 2023 | 2023-03-31 | ¥61.02B | ¥17.29B | +39.55% |
| 2022 | 2022-03-31 | ¥43.73B | ¥4.30B | +10.91% |
| 2021 | 2021-03-31 | ¥39.43B | ¥9.41B | +31.36% |
| 2020 | 2020-03-31 | ¥30.02B | ¥11.23B | +59.77% |
| 2019 | 2019-03-31 | ¥18.79B | −¥3.38B | −15.27% |
| 2018 | 2018-03-31 | ¥22.17B | ¥4.76B | +27.32% |
| 2017 | 2017-03-31 | ¥17.41B | — | — |
Takeda Pharmaceutical quarterly stock-based compensation
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-03-31 | ¥19.71B | ¥2.08B | +11.82% |
| Q3 2026 | 2025-12-31 | ¥17.80B | — | — |
| Q2 2026 | 2025-09-30 | ¥18.73B | — | — |
| Q1 2026 | 2025-06-30 | ¥16.53B | — | — |
| Q4 2025 | 2025-03-31 | ¥17.63B | — | — |
Takeda Pharmaceutical stock-based compensation trends
Over the last five fiscal years, Takeda Pharmaceutical's stock-based compensation increased from ¥39.43B to ¥72.78B, a change of ¥33.35B. The latest reported quarter, Q4 2026, shows ¥19.71B.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Takeda Pharmaceutical source filings ↗